COMMUNIQUÉS West-GlobeNewswire

New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
09/02/2024
BOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation of preliminary data from The S quid T rial for the E mbolization of the M iddle [...]
PickleJar Debuts "Win Now" Technology to Simplify Contesting Programs With Strategic Partners and Reward Fans
09/02/2024
HOUSTON, TX, Feb. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PickleJar Entertainment Group, f/k/a NewRegen, Inc. (OTC:NREG) , a leading Texas-based music and entertainment software company, today announced new [...]
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
09/02/2024
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their [...]
Coloplast A/S - Allocation of Share Options
09/02/2024
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives [...]
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market
09/02/2024
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced the acquisition of all the issued and outstanding [...]
MedBright AI Announces Closing of LIFE Offering for Gross Proceeds of Approximately $1.4 Million
09/02/2024
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. ( CSE: MBAI ) ( [...]
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station
09/02/2024
(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space [...]
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09/02/2024
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, [...]
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
09/02/2024
WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Caira Surgical to Present Innovative Radar Surgical Tracking at CG 2024 Musculoskeletal Conference
09/02/2024
CEO Jon Greenwald to Present at 4:30 p.m. in the Georgian Room NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Caira Surgical, the pioneer in Radar Surgical Tracking for robotic and navigated joint replacement surgery, [...]
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09/02/2024
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
09/02/2024
- Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing regions - NEW YORK, [...]
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09/02/2024
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light Holland VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ”) (CSE: MDMA) (OTC: [...]
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
09/02/2024
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
OneMedNet Sees Real World Data Growth in Women’s Health
09/02/2024
MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“RWD”), today announced a growth [...]
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
09/02/2024
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of [...]
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
09/02/2024
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines [...]
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
09/02/2024
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]
Coloplast Finance B.V. - Interim Financial Report, Q1 2023/24
09/02/2024
Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin 1) of 28%. Reported revenue in DKK grew 8% with 4%-points [...]

Pages